INTRODUCTION
Female genital mutilation/cutting (FGM/C) includes all procedures that involve removal or injury of female genital organs for non-medical reasons. FGM/C exists in many regions of the world including Africa, Asia, the Middle East, some regions of Central and South America, and, with migration, high income countries as well. According to the World Health Organization (WHO), more than 200 million women across the world are living with FGM/C. At least half a million women are estimated to be affected or at risk in Europe and in the United States.
The WHO classifies FGM/C into 4 types (Table 1). FGM/C can cause immediate and long-term health complications. Immediate complications include psychological consequences but also urinary lesions, impaired healing, infections (e.g. tetanus or HIV), severe genital pain, hemorrhage, shock and death. Late complications can occur at any time during the girl and/or woman’s life and include psychological, genitourinary, obstetric, sexual and infectious complications, as well as chronic pain such as chronic genito-pelvic pain, including dyspareunia and chronic vulvar pain.

Chronic vulvar pain can be divided into 2 categories: vulvar pain caused by a specific disorder, including trauma such as FGM/C; and vulvodynia, referring to vulvar pain of unknown origin of at least 3 months. The prevalence of chronic vulvar pain in the general population ranges from 3 to 15% in self-report studies. The pain can be generalized or localized, to one specific part of the vulva, such as the clitoris. It can be provoked (by contact, menstruation, sexual intercourse) or unprovoked (without contact) or mixed. The development and persistence of chronic vulvar pain among women with and without FGM/C is associated with biological, psychological and inter-relational factors. In case of FGM/C, biological factors can include the type of cutting, its severity and complications, past obstetric traumas, recurrent genitourinary infections, recurrent fissures or ulcers, abscesses, post traumatic granulomas and neuromas, vulvar, or clitoral cysts, keloids, and adhesions, or bridles. Psychological factors that are associated with chronic vulvar pain include depression, anxiety, and Post-traumatic Stress Disorder (PTSD). Furthermore, social and personal coping strategies of the experience of FGM/C may influence the pain experience. Although FGM/C may be a physically and psychologically traumatic event, a considerable number of women are capable of coping with most impediments and may regard the ritual as “normal” or “enhancing.” Diversity in the interpretation, the memory and the experience of the event is crucial for pain psychopathology. Some specific painful experiences such as labor, delivery and post-vulvar surgery pain can recall the pain of the FGM/C, triggering anxiety, depression, or relapse of a PTSD. Relational and social factors that may be associated with chronic vulvar pain involve education and misconceptions about FGM/C, about female genital anatomy and physiology and about female sexuality. Furthermore, beliefs and cultural significance of sexuality and migration may influence chronic pain. For example, previous research has shown that young migrant women with FGM/C that grow up in the West and are exposed to negative or stigmatizing messages on their genital cutting, are at increased risk of sexual problems or a negative self-body/genitals perception.

Finally, many women with FGM/C may have lived other past traumatic events that can contribute to the onset or maintaining of chronic pain (eg, rape, war, migration, death of family members/losses, forced and child marriage, reinfibulation after rape or after delivery).

Previous research has shown that chronic vulvar pain can significantly affect the quality of life of women with FGM/C. However, little is known about the bio-psycho-social etiologic factors of chronic vulvar pain after FGM/C. Most knowledge comes from expert opinions and from a few single center case series or reports, mainly on vulvar cysts, clitoral neuromas and defibilation. Research mainly focuses on FGM/C type III which represents 10% of FGM/C. Furthermore, a recent mixed-method study on 14 infibulated Somali-Canadian women, focusing on the connection between peripheral nerve damage and chronic neuropathic pain, found that the participants reported low levels of pain on the Short-Form McGill Pain Questionnaire-2 while their vulvar pain thresholds were consistent with those reported by uncut women with chronic vulvar pain and dysmenorrhea. The authors of this study insist on how assessing chronic vulvar pain can be challenging due to cultural differences influencing the way pain is experienced, described and verbalized. This study asks the following research questions. What are the prevalence, etiologies and possible biological, psychological and social factors of chronic vulvar pain in women with different types of FGM/C? Are the pain symptoms of women with FGM/C type III (infibulation) different from those of women having undergone other types of cutting that do not involve the narrowing of the vaginal introitus?

Table 1. FGM/C classification according to the World Health Organization

| Types of FGM/C                        | Description                                                                 |
|---------------------------------------|-----------------------------------------------------------------------------|
| Type I (clitoridectomy)               | Ia Removal/Cutting of the prepuce/clitoral hood                             |
|                                       | Ib Removal/Cutting of glans with eventually part of the body of the clitoris |
| Type II (excision)                    | Iia Removal/Cutting of inner labia                                          |
|                                       | Iib Removal/Cutting of inner labia associated to cutting of the clitoris    |
|                                       | Iic Removal/Cutting of inner labia associated to cutting of the clitoris and outer labia |
| Type III (infibulation)               | Ila Removal/Cutting and apposition of inner labia (with or without excision of the clitoris) |
|                                       | Iib Removal/Cutting and apposition of outer labia (with or without excision of the clitoris) |
| Type IV (all other practices)         | Piercing, scraping, incising, pricking or cauterizing of the genital area. Stretching of the inner labia |

*Female genital mutilation. (n.d.). From https://www.who.int/news-room/fact-sheets/detail/female-genital-mutilation
MATERIALS AND METHODS

We retrospectively reviewed the consecutive medical files of women who consulted at the specialized clinic for women with FGM/C at the Gynecology Division of the Geneva University Hospitals between April 1, 2010 and December 31, 2017. The FGM/C clinic is an outpatient clinic where women and girls with FGM/C consult or are referred for different reasons, for example, information on FGM/C, counseling, health complications related to FGM/C, psychosexual care, perinatal care or request for defibulation or other surgical interventions.

Women and girls who consulted at the clinic during the predefined period were included. They were examined by 2 specialized gynecologists trained in vulva disease and sexual medicine who run the clinic. Patients were comprehensively and systematically interviewed on bio-psycho-social issues, including information on FGM/C, age and setting at which it was performed, immediate and late complications. Psychosexual and mental health, as well as chronic pain (eg, vulvar) and its characteristics were systematically investigated during the anamnesis. Pelvic examination always involved vulvar, anal, and perineal inspection. Depending on the patient, the type of genital cutting, her history, her symptoms, and the consultation’s reasons, a speculum and a bimanual examination, a cotton-swab test, pelvic floor assessment and screening of recurrent infections and candidiasis were also performed.26–28

In absence of language barriers, a woman is received alone for all or for part of the consultation if she asks her partner, friend or family member to be in the room. The presence of an interpreter might cause the loss of some information or embarrassment in the patient. However, everything is done to minimize this: when an appointment is scheduled by women and girls who do not speak one of the languages spoken by the gynecologists, a female certified interpreter is scheduled as well. The female interpreters work for the Red Cross of Geneva; are trained and certified; trusted, well known and accepted in the communities. They participate in person to the consultation with no additional costs for the patient. During the clinical examination, depending on the patient’s wishes, the interpreter remains behind a curtain or leaves the room momentarily. Our interpreters were also trained in FGM/C and female and sexual and reproductive health in a training program organized several years ago by the equality office of the Geneva Canton. They also routinely translate in our prospective research studies or during surgical procedures under local or locoregional anesthesia.

We collected sociodemographic and clinical data including information on the type of FGM/C and its complications and other accidental traumas. We focused on studying the prevalence, etiologies and characteristics of chronic vulvar pain. Given the retrospective nature of the study, information on cotton-swab test and pelvic floor assessment was not always documented in the medical files and for this reason, we did not focus our analysis on it. Informed consent was waived: re-contacting all women by phone would have been difficult because of language barriers and frequent changes in contact details. The study research protocol was approved by the Institutional Review Board.

Statistical analysis was performed using IBM SPSS Statistics 25.0. Descriptive statistics are reported, both as numbers and percentages. Chi-square and t-test were applied to investigate differences between the population of women with FGM/C type III versus the population of women without infibulation (FGM/C type I, II and IV). Statistical significance was set at $P < .05$.

RESULTS

We reviewed 506 medical charts of patients with FGM/C who attended our clinic. Our population was averagely 29.70 ± 7.99 years old, with a minimum age of 10 and a maximum age of 82 years old.

Information on the date of arrival in Switzerland was available for 215 (42.5%) women who had averagely spent a period of 4.37 ± 6.42 years in Switzerland, with a minimum of 1 month and a maximum of 35 years.

As summarized in Table 2, women were mainly born in Africa, mostly in East Africa. Four women were born in non-African countries: 2 (0.4%) in Asia and 2 (0.4%) in countries of Europe different than Switzerland (France and Portugal). One woman (originally from Mali) had undergone the cutting in her EU country and the other woman (originally from Guinea) during a trip to her original country.

Most women were Muslim (n = 201, 39.7%) and married (n = 306, 60.5%) or in a relationship (n = 97, 19.2%), involving sex.

Almost half of the sample (n = 245, 48.4%) needed a certified interpreter due to language barriers.

The majority of girls and women (n = 256, 50.6%) had undergone FGM/C type III (infibulation) (Table 3). Five women reported FGM/C in their medical history but presented with no visible scar during clinical examination, suggesting a possible FGM/C without removal of tissue or scar (eg, pricking or scraping). For 23 women, a written documentation of FGM/C type was unavailable, because they were not examined (eg, refusal) (n = 7), did not attend the appointment for gynecological examination (n = 8) or FGM/C documentation was missing in the medical chart (n = 8).

Among women from Eritrea, Guinea, Burkina Faso, Mali and Senegal, FGM/C type II and III were equally frequent. Somali and Sudanese women were mostly infibulated (Table 4).

Late complications, referred as associated to FGM/C by the women, included chronic genito-pelvic pain (n = 183, 36.2%) such as dyspareunia, dysmenorrhea, vulvar pain, abdominal, pelvic or bladder pain; scar complications (n = 39, 7.7%) such as vulvar cysts, bridle scars or post-traumatic neuromas; recurrent
genitourinary infections (n = 11, 2.2%) and, sexual dysfunction (n = 143, 28.3%) (Table 5). Some women reported to suffer from several co-existent complications.

Among the 183 women who suffered from genito-pelvic pain, the majority (n = 126, 68.8%) reported dyspareunia (Table 5): 75 patients (14.8%) suffered from superficial dyspareunia while 25 patients (4.9%) complained of deep dyspareunia. 14 (2.8%) women complained from both superficial and deep dyspareunia. Finally, 12 women (2.4%) reported dyspareunia with no specified localization in the medical charts.

Chronic vulvar pain defined as vulvar pain for at least 3 months, provoked or unprovoked, was found in 14 (2.8%) girls and women (Table 6). Most of these (n = 12, 85.7%) had scar complications such as painful vulvar cysts (n = 6, 42.9%). Vulvar pain was mostly provoked by contact (eg, crossing legs, touching) (n = 13, 92.9%). One patient (7.1%) presented with a painful clitoral scar with constant and unprovoked vulvar pain. Among these 14 women, 12 suffered from superficial dyspareunia as well. The remaining ones had not had any sexual contact for several years.

Twenty-one women presented with a vulvar cyst (Table 7), among which only 6 (28.6%) were painful. The histological characteristics of both painful and painless resected cysts (n = 10, 47.6%) are summarized in Table 7. Painful cysts included 1 neuroma, 1 mullerian cyst, and 3 epidermoid cysts. Most of the cysts were a complication of FGM/C type III (Table 8). Two women had a history of a previous vulvar cystectomy performed in another clinic. Both were asymptomatic at the moment of their examination and no information about eventual past genital pain was reported in their medical files.

Information about age at which FGM/C was performed, was available in 198 files (39%). Age at excision was higher in women with genito-pelvic pain (mean age at FGM/C 6.22 ± 4.47 years; median 7 years, IQR 0.75–9 years) compared to women without genito-pelvic pain (mean age at FGM/C 3.85 ± 5.13 years; median 1 year, IQR 0–7.5 years). This was also the case for the subgroup of women with chronic vulvar pain who had a higher median age at excision (mean age at FGM/C 8.32 ± 3.68 years; median 8.5, IQR 8–10.75 years) compared to women without chronic vulvar pain (mean 4.79 ± 4.98 years; median 5, IQR 0–8 years).

Among women with chronic vulvar pain, 35.7% (n = 5) had a history of past traumatic events other than FGM/C and 28.6% (n = 4) had psychiatric comorbidities (3 suffered from PTSD and 1 from depression). Also, 28.6% women with vulvar pain (n = 4) complained of a negative self-image.

The prevalence of chronic pain was similar among women who required the presence of a certified interpreter (n = 84,
34.5% of 245 women) and who did not (89, 33% of 231). The same was for chronic vulvar pain: 6 women did not require translation and 7 did.

We compared infibulated women (FGM/C type III) and cut but noninfibulated women (FGM/C types I, II and IV) to assess vulvar pain symptoms and dyspareunia. In order to limit classification bias, we only included women with a visible scar and a documented type of FGM/C. As summarized in Table 9, the presence of referred late complications in general \((P = .007)\), sexual dysfunctions \((P = .015)\), dyspareunia \((P = .014)\) were significantly more frequent among women with FGM/C type III. Vulvar cysts were also found more frequently in women with FGM/C type III. Vulvar pain was equally frequent in infibulated women \((n = 6)\) and noninfibulated women \((n = 7)\).

Almost one third of women \((n = 145, 28.7\%)\) reported sexual dysfunction such as lack of or low desire \((n = 9, 1.8\%),\) anorgasmia \((n = 9, 1.8\%)\) and, mainly, dyspareunia \((n = 102, 20.2\%)\) as summarized in Table 5. Dyspareunia was reported by 126 women, 24 of whom had other sexual dysfunctions associated.

In 21 (4.2%) medical charts, a self-reported negative genital image was documented. Women with such negative genital self-image had lived for a significantly longer amount of time in Switzerland in comparison with women who did not actively complain of low self-body image \((P < .001)\).
In seventy-three women (14.4%), past traumatic events such as war, rape, forced marriage, domestic violence or violence during migration were documented in the medical file.

Psychiatric comorbidities such as depression, anxiety and PTSD (that may be linked to other factors than FGM/C alone) were documented in 65 women (12.8%).

DISCUSSION

It has already been shown that women with FGM/C have higher risks of experiencing dyspareunia than women without FGM/C.\(^{29}\) In our study, we aimed to assess the prevalence and possible etiologies of chronic vulvar pain, by retrospectively analyzing the records of 506 women who attended our specialized FGM/C outpatient clinic between 2010 and 2017.

Chronic vulvar pain was present in 2.8% of our patients with FGM/C. Previous studies on women without FGM/C reported a lifetime prevalence of chronic vulvar pain ranging from 3 to 15%.\(^{7,8}\) However, prevalence of current chronic vulvar pain (point prevalence at the time of the survey) ranged between 1.6 and 7%.\(^{7,8}\) Our study is retrospective and does not assess all previous experiences of chronic vulvar pain. It retrieves information about active complaints of pain that were recorded in the medical file. Still, our numbers may be underestimated for different reasons. Many uncut women with chronic vulvar pain do not seek medical help for it\(^{30}\) and 45.1% of the women who do seek medical care, feel stigmatized by physicians.\(^{30}\) Women and girls with FGM/C might fear even more stigma and consult less because of socioeconomic, cultural and language barriers and the stigma surrounding FGM/C in diaspora countries.\(^{16}\) The safeguarding approach and discourse around FGM/C have indeed increased stigmatization and disconnection with the healthcare system.\(^{31}\)

Some authors have also suggested that the population of women with FGM/C have socio-cultural backgrounds that may affect the way they experience and verbalize vulvar pain.\(^{25,52}\) Thus, comparing our results with a prevalence found in a mainly Western and Caucasian population might be misleading. Jacobson and colleagues showed that many patients with FGM/C accepted chronic pain as being a normal part of a woman’s life and did not necessarily associate their pain with FGM/C-related

| Table 6. Chronic provoked and unprovoked vulvar pain (n tot=14) |
|-----------------|----------------|----------------|
| Vulvar pain     | Types of FGM/C | Scar complications |
| Provoked (n = 13)* | II: n = 1 | Vulvar cysts (n = 6) |
|                 | III: n = 4 | |
| Undocumented:   | I: n = 1 | Bridle and scar tissue complications (n = 5) |
|                 | II: n = 3 | |
|                 | III: n = 1 | Peri-clitoral adhesions (n = 1) |
|                 | II: n = 1 | No scar tissue (n = 1) |
| Unprovoked (n = 1) | III: n = 1 | Post-reinfibulation vulvar wound (n = 1) |

*Among women with provoked chronic vulvar pain, 11 also suffered from superficial dyspareunia while 2 had no sexual intercourse at the moment of the assessment.

1This woman also suffered from adenomyosis and had a suspicion of endometriosis.

| Table 7. Histological characteristics of resected cysts |
|-----------------|----------------|
| Histology of cysts, n (%) | Painful cysts, n (%) |
| Epidermal 8 (38.1) | 3 (37.5) |
| Mullerian 1 (4.8) | 1 (100) |
| Neuroma 1 (4.8) | 1 (100) |
| Total 10 (100) | 5 (100) |

| Table 8. Vulvar cysts according to type of FGM/C |
|-----------------|----------------|
| Type | n (%) |
| Type I | 0 (0) |
| Type II | 2 (9.5) |
| Type III | 18 (85.7) |
| Type IV | 0 (0) |
| Not documented | 1 (4.8) |
| Total | 21 (100) |

| Table 9. Infibulated vs noninfibulated but cut women |
|-----------------|----------------|
| Infibulated women (n = 256) | Non-infibulated women (n = 222) |
| Late complications (n = 141) | Pain (n = 178) |
| 89 (34.8) | 52 (23.4) |
| P value | .007 |
| Dyspareunia (n = 122) | 77 (30.1) |
| 45 (20.3) | .014 |
| Dysmenorrhea (n = 95) | 52 (20.3) |
| 43 (19.4) | .797 |
| Vulvar pain (n = 13) | 6 (2.3) |
| 7 (3.2) |
| Vaginismus (n = 6) | 5 (2.0) |
| 1 (0.5) |
| Vulvar cysts (n = 20) | 18 (7.0) |
| 2 (0.9) | .001 |
| Recurrent infections (n = 11) | 9 (3.5) |
| 2 (0.9) |
| Sexual dysfunction (n = 140) | 87 (34.0) |
| 53 (23.9) | .015 |
| Negative self-image (n = 20) | 9 (3.5) |
| 11 (5.0) | .433 |
complications. In some settings, some women endured pain in silence as they saw pain as valuable and an integral part of a meaningful ritual that is FGM/C. Remaining stoic about pain was found to be expected in certain cultures such as the Somali one and expressing suffering and pain was found to be seen as shameful in a study on women from Djibouti, Eritrea, Ethiopia and Somalia. A recent study showed that a small sample of Somali-Canadian infibulated women reported low pain levels on validated pain questionnaires and reported good general health while having pain thresholds as low as other women with chronic vulvar pain during quantitative sensory pain testing in the vulvar area. Only when the participants were handed open-ended questionnaires, leaving space for self-expression of pain, did they report chronic disabling daily pain. In our population, vulvar pain was linked to infibulation and vulvar scar complications, such as cysts, neuromas, scar tissue and bridles. As we present in another manuscript currently under review, surgical excision of such complications can reduce and treat such pain symptoms.

However, chronic vulvar pain is known to be associated to other factors and cofactors in addition to FGM/C, such as pelvic floor hypertonia, recurrent genito-urinary infections and previous obstetric perineal trauma that could not be comprehensively assessed in our retrospective study and remain to be investigated.

Psychological and psychiatric factors can also be associated to chronic vulvar pain. 14.4% of the medical charts mentioned past traumatic events (war, rape, forced marriage, domestic violence, or violence during migration) and 12.8% psychiatric comorbidities such as depression, anxiety or PTSD, confirmed by the psychiatrist and/or psychologist of the outpatient clinic. PTSD as well as depression can mutually maintain pain and be responsible for or worsen sexual dysfunction and negative self-image. We found that an active complaint of negative self-image was significantly associated with a longer time spent in Switzerland. Stigma surrounding FGM/C in diaspora countries can be responsible for low self-esteem and feelings of abnormality, shame and deep aversion towards the own external genitalia, contributing to psychological and sexual difficulties. The rate of past violent events different from FGM/C. However, FGM/C, especially type III, might contribute to it, through recurrent genital infections, particularly vaginosis that might lead to Pelvic Inflammatory Disease (PID), and eventually, deep dyspareunia. In addition, painful or impossible and/or difficult penetration might lead to deep and superficial pelvic floor hypertonicity, also participating in chronic pain pathophysiology.

The discrepancy between the prevalence of chronic vulvar pain and that of dyspareunia confirms what we observe in our clinical practice. It can also be explained by the characteristics of our sample, half of whom are infibulated. Infibulation is a mechanical barrier to vaginal penetration responsible for pain during sex, sometimes impossible penetration, and possibly recurrent lesions, fissures and consequent tissue inflammation. Chronic vulvar pain was more frequent among women with scar complications such as neuromas, cysts, bridles and eventually infibulation.

Limitations of the study are mainly explained by its retrospective nature. A standardized assessment of pain intensity, pain localization and pain affect has not been performed: also, all women did not systematically undergo swab tests or pelvic floor exams, rendering the calculation of the prevalence of related diagnoses such as vulvodynia or pelvic floor hypertonia difficult.

The same is true for the assessment of sexual function which was not investigated through validated questionnaires. Furthermore, among infibulated women, we could not retrospectively differentiate between those who had and those who had not undergone cutting of their clitoris as this was not always documented. Also, our study included only 3 women with FGM/C type IV whose complications remain a research gap. Knowing that FGM/C is a risk factor for episiotomy and severe perineal tears, we presume that past obstetric perineal traumas might also contribute to pain. Such information was not studied.
Finally, most of the women in our sample had FGM/C type III which is not representative of the distribution of types of FMRGC in the world, where infibulation represents 10% of all affected women. This is due to the fact that our population is largely composed of Somali and Sudanese women, countries in which infibulation is most likely to occur and that our study was conducted in a specialized clinic where women are often referred by other health professionals after detection of FGM/C and its complications, infibulation being the easiest type to detect and the one mostly associated to complications.

Strengths of this study are the size of the sample of women coming from several ethnic, cultural and religious backgrounds with different types of FGM/C and the use of well-documented computerized medical records of a specialized outpatient clinic run by 2 gynecologists trained in sexual medicine, vulva disease and management of FGM/C. Women who came to our specialized clinic over a period of 7 years, were all examined by these providers only. This guarantees a consistent and reliable classification and documentation of FGM/C types and complications, pain assessment, psychosexual response and history of trauma other than FGM/C. Data was retrieved by 1 author (YB) different from the 2 examining physicians. Finally, a major strength of our study is the availability of the histological results in case of surgical resection of the cysts for a better understanding of pathophysiological etiology of pain.

Future prospective studies could assess lifetime as well as point prevalence of chronic vulvar pain and dyspareunia in women with FGM/C, possibly using standardized, quantitative and qualitative tools, taking into account the cultural differences in expression of pain. They could also explore pelvic muscle floor dysfunctions as a potential contributory cause of chronic pain. Also, both superficial and deep dyspareunia and their prevalence in different types of FGM/C remain to be further investigated. Finally, the eventual impact of the presence of certified interpreters in the pain symptoms recollection and, as it has already been explored by previous studies on women with genital pain, the role of psychological factors and the role of the partner on the onset and persistence of chronic pain could be further explored. Implications for clinical practice include a multidisciplinary approach of chronic vulvar pain with the consideration of FGM/C and its consequences and the psychosocial aspects that can be related to chronic pain. Women with a sexual dysfunction should be offered comprehensive psychosexual care with counseling and psychosexual therapy.

CONCLUSIONS

Women with FGM/C are at risk of developing dyspareunia and vulvar scar complications, possibly causing chronic vulvar pain. Dyspareunia is mostly present in infibulated women. Vulvar and clitoral pain seem equally frequent in both infibulated and cut, noninfibulated, women. Physical factors that may provoke pain include scar complications such as vulvar cysts, briddles, post-traumatic neuromas or the mechanical obstacle of infibulation. Specific psychological complications of FGM/C and socio-cultural factors may also interact with pain and sexual function.

Girls and women with FGM/C suffering from pain, should be informed, investigated and treated according to the best available scientific evidence, in a comprehensive, multidisciplinary, respectful, and culturally sensitive way.

Corresponding Author: Jasmine Abdulcadir, MD PD, Division of Gynaecology, Department of Paediatrics, Gynaecology and Obstetrics, Geneva University Hospitals, 30 Bld de la Cluse, Geneva 1211, Switzerland. Tel: 0041223724049; E-mail: jasmine.abdulcadir@hcuge.ch

Conflict of Interest: The authors report no conflicts of interest.

Funding: None.

STATEMENT OF AUTHORSHIP

Conceptualization, J.A.; Methodology, J.A. and Y.B.; Investigation, Y.B.; Writing – Original Draft, Y.B and J.A.; Writing – Review & Editing Y.B. and J.A. and L.A.; Supervision, J.A. and L.A.

REFERENCES

1. “Female genital mutilation.” Available at: https://www.who.int/news-room/fact-sheets/detail/female-genital-mutilation. Accessed April 03, 2021.
2. “WHO eliminating female genital mutilation,” WHO. Available at: http://www.who.int/reproductivehealth/publications/fgm/9789241596442/en/. Accessed April 03, 2021.
3. “Female genital mutilation (FGM) statistics,” UNICEF DATA. Available at: https://data.unicef.org/topic/child-protection/female-genital-mutilation/. Accessed April 03, 2021.
4. “FGM in Europe,” End FGM. Available at: https://www.endfgm.eu/female-genital-mutilation/fgm-in-europe/. Accessed April 13, 2021.
5. Goldberg H, Stupp P, Okoroh E, et al. Female genital mutilation/cutting in the United States: Updated estimates of women and girls at risk, 2012. Public Health Rep 2016;131:340–347 Wash. DC 1974. doi: 10.1177/003335491613100218.
6. Bornstein J, Goldstein AT, Stockdale CK. 2015 ISSVD, ISSWSH, and IPPS consensus terminology and classification of persistent vulvar pain and vulvodynia. J Sex Med 2016;13:607–612. doi: 10.1016/j.jsxm.2016.02.167.
7. Harlow BL, Stewart EG. A population-based assessment of chronic unexplained vulvar pain: have we underestimated the prevalence of vulvodynia? J Am Med Womens Assoc 1972 2003;58:82–88.
Chronic Vulvar Pain After FGM/C

8. Reed BD, Crawford S, Couper M, et al. Pain at the vulvar vestibule: a web-based survey. J Low Genit Tract Dis Jan. 2004;8:48–57. doi: 10.1097/00128360-200401000-00011.

9. Reed BD, Haefner HK, Harlow SD, et al. Reliability and validity of self-reported symptoms for predicting vulvodynia. Obstet Gynecol 2006;108:906–913. doi: 10.1097/01.AOG.0000237102.70485.5d.

10. Pukall CF, Goldstein AT, Bergeron S, et al. Vulvodynia: definition, prevalence, impact, and pathophysiological factors. J Sex Med 2016;13:291–304. doi: 10.1016/j.jsxm.2015.12.021.

11. Abdulcadir J, Catania L, Hindin MJ, et al. Female genital mutilation/cutting: a visual reference and learning tool for health care professionals. Obstet Gynecol 2016;128:958–963. doi: 10.1097/AOG.0000000000001686.

12. Abdulcadir J, Tille J-C, Petignat P. Management of painful clitoral neuroma after female genital mutilation/cutting. Reprod Health 2017;14:222. doi: 10.1186/s12978-017-0288-3.

13. Iglesias-Rios L, Harlow SD, Reed BD. Depression and post-traumatic stress disorder among women with vulvodynia: evidence from the population-based woman to woman health study. J Womens Health 2015;24:357–362. doi: 10.1089/jwh.2014.5001.

14. Knipscheer J, Vloerberghs E, van der Kwaak A, et al. Mental health problems associated with female genital mutilation. BJPsych Bull 2015;39:273–277. doi: 10.1192/pb.bp.114.047944.

15. Abdulcadir J, Bianchi Demicheli F, Willame A, et al. Post-traumatic stress disorder relapse and clitoral reconstruction after female genital mutilation. Obstet Gynecol 2017;129:371–376. doi: 10.1097/AOG.0000000000001835.

16. Johnsdotter S. The impact of migration on attitudes to female genital cutting and experiences of sexual dysfunction among migrant women with FGC. Curr Sex Health Rep 2018;10:18–24. doi: 10.1007/s11930-018-0139-4.

17. Abdulcadir J, Catania L. Conceptualizing sexual pain in women with female genital mutilation/cutting. Arch Sex Behav 2020. doi: 10.1007/s10508-020-01691-1.

18. Sigurjonsson H, Jordal M. Addressing female genital mutilation/cutting (FGM/C) in the era of clitoral reconstruction: Plastic surgery. Curr Sex Health Rep 2018;10:50–56. doi: 10.1007/s11930-018-0147-4.

19. Ezebialu I, Okao O, Oringanje C, et al. Surgical and nonsurgical interventions for vulvar and clitoral pain in girls and women living with female genital mutilation: A systematic review. Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet 2017;136(Suppl 1):34–37. doi: 10.1002/ijgo.12048.

20. Rouzi AA. Epidermal clitoral inclusion cysts: Not a rare complication of female genital mutilation. Hum Reprod Oxf Engl 2010;25:1672–1674. doi: 10.1093/humrep/deq126.

21. Abdulcadir J, Pusztaszeri M, Vilarino R, et al. Clitoral neuroma after female genital mutilation/cutting: A rare but possible event. J Sex Med 2012;9:1220–1225. doi: 10.1111/j.1743-6109.2011.02558.x.

22. Catania L, Abdulcadir O, Puppo V, et al. Pleasure and orgasm in women with female genital mutilation/cutting (FGM/C). J Sex Med 2007;4:1666–1678. doi: 10.1111/j.1743-6109.2007.00620.x.

23. Nour NM, Michels KB, Bryant AE. Defibulation to treat female genital cutting: Effect on symptoms and sexual function. Obstet Gynecol 2006;108:55–60. doi: 10.1097/01.AOG.0000224613.72892.77.

24. Shifren JL, Monz BJ, Russo PA, et al. Sexual problems and distress in United States women: Prevalence and correlates. Obstet Gynecol 2008;112:970–978. doi: 10.1097/AOG.0b013e181898cdeb.

25. Perovic M, Jacobson D, Glazer E, et al. Are you in pain if you say you are not? Accounts of pain in Somali-American women with female genital cutting (FGC). Pain 2020. doi: 10.1097/j.
pain.0000000000002021.

26. Vieira-Baptista P, Lima-Silva J, Beires J, et al. Women without vulvodynia can have a positive ‘Q-tip test’: A cross-sectional study. J Psychosom Obstet Gynaecol 2017;38 (4):256–259. doi: 10.1080/0167482X.2017.1327519.

27. Muñoz JM, Beausang J, Finley E, et al. Protocol for evaluating women with female genital mutilation seeking asylum. Int J Legal Med 2020;134(4):1495–1500. doi: 10.1007/s00414-019-02213-y.

28. The utility of and indications for routine pelvic examination. Available at: https://www.acog.org/en/clinical/clinical-guidance/committee-opinion/articles/2018/10/the-utility-of-and-indications-for-routine-pelvic-examination. Accessed June 28, 2021.

29. Lucie JM, Weidman A, Huynh S, et al. Painful gynecologic and obstetric complications of female genital mutilation/cutting: A systematic review and meta-analysis. PLOS Med 2020;17:e1003088. doi: 10.1371/journal.pmed.1003088.

30. Nguyen RHN, Turner RM, Rydell SA, et al. Perceived stereotyping and seeking care for chronic vulvar pain. Pain Med Malden Mass 2013;14:1461–1467. doi: 10.1111/j.1349-0136.2013.00620.x.

31. Abdelshahid A, Smith K, Habane K. “Do no harm”. Lived experiences and impacts of FGM safeguarding policies and procedures. Bristol study 2021. doi: 10.34696/ERCS-2V52.

32. Arnold LD, Bachmann GA, Rosen R, et al. Assessment of vulvodynia symptoms in a sample of US women: a prevalence survey with a nested case control study. Am J Obstet Gynecol 2007;196:128.e1–128.e6. doi: 10.1016/j.ajog.2006.07.047.

33. Jacobson D, Glazer E, Mason R, et al. The lived experience of female genital cutting (FGC) in Somali-Canadian women’s daily lives. PLOS ONE 2018;13:e0206886. doi: 10.1371/journal.pone.0206886.

34. Finnström B, Söderhamn O. Conceptions of pain among Somali women. J Adv Nurs 2006;54:418–425. doi: 10.1111/j.1365-2648.2006.03838.x.

35. Isman E, Eküüs C, Berggren V. Perceptions and experiences of female genital mutilation after immigration to Sweden: An explorative study. Sex Reprod Healthc Off J Swed Assoc Midwives 2013;4:93–98. doi: 10.1016/j.srhc.2013.04.004.
36. Sharp TJ, Harvey AG. Chronic pain and posttraumatic stress disorder: Mutual maintenance? Clin Psychol Rev 2001;21:857–877. doi: 10.1016/s0272-7358(00)00071-4.

37. Sreelakshmy K, Velayudhan R, Kuriakose D, et al. Sexual dysfunction in females with depression: A cross-sectional study. Trends Psychiatry Psychother 2017;39:106–109. doi: 10.1590/2237-6089-2016-0072.

38. Binkova A, Uebelhart M, Dällenbach P, et al. A cross-sectional study on pelvic floor symptoms in women living with female genital mutilation/cutting. Reprod Health 2021;18:39. doi: 10.1186/s12978-021-01097-9.

39. Foldes P, Cuzin B, Andro A. Reconstructive surgery after female genital mutilation: A prospective cohort study. Lancet Lond Engl 2012;380:134–141. doi: 10.1016/S0140-6736(12)60400-0.

40. Mitchell K, Geary R, Graham CA, et al. Painful sex (dyspareunia) in women: prevalence and associated factors in a British population probability survey. BJOG 2017;124:1689–1697. doi: 10.1111/1471-0528.14518.

41. Berg RC, Underland V, Odgaard-Jensen J, et al. Effects of female genital cutting on physical health outcomes: A systematic review and meta-analysis. BMJ Open 2014;4:e006316. doi: 10.1136/bmjopen-2014-006316.

42. Rodriguez MI, Seuc A, Say L, et al. Episiotomy and obstetric outcomes among women living with type 3 female genital mutilation: A secondary analysis. Reprod Health 2016;13. doi: 10.1186/s12978-016-0242-9.

43. “Female genital mutilation (FGM) frequently asked questions.” /pcm/node/9481 (Accessed Apr. 03, 2021).

44. Rosen NO, Rancourt KM, Corsini-Munt S, et al. Beyond a ‘woman’s problem’: the role of relationship processes in female genital pain. Curr Sex Health Rep 2014;6:1–10. doi: 10.1007/s11930-013-0006-2.